Tirzepatide is unique as it is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, which means it targets two natural incretin hormones, offering potentially even greater benefits for blood sugar control and weight reduction
For injectable use, both formulations deliver essentially identical results because the peptide bypasses the gastrointestinal tract entirely
Diabetes Obes Metab 23(9):21162124 Buse JB, Bode BW, Mertens A, Cho YM, Christiansen E, Hertz CL, Nielsen MA, Pieber TR (2020) Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
Although these cases are not common, they raise important questions
If retatrutide is approved in the future, patients losing weight quickly may need advice on protein intake, nutrition and safe weight loss monitoring
Discontinuation was defined as a 90-day gap from the last date of GLP-1 RA supply to the first date of subsequent prescription claim